Central Trust CO Bei Gene, Ltd. Transaction History

Central Trust CO

$4.19 Billion
Q3 2024

A detailed history of Central Trust CO transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Central Trust CO holds 1 shares of BGNE stock, worth $184. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Holding current value

$184

% of portfolio

0.0%

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 22, 2024	BUY	$143.93 - $224.51 $143 - $224	1 New	1 $0
Q2 2020 Jul 14, 2020	SELL	$123.9 - $195.41 $4,956 - $7,816	-40 Closed	0 $0
Q2 2019 Jul 12, 2019	BUY	$113.99 - $146.86 $4,559 - $5,874	40 New	40 $0

Others Institutions Holding BGNE

# of Institutions

252

Shares Held

45.3M

Call Options Held

292K

Put Options Held

119K

Baker Bros. Advisors LP New York, NY

10.6M
Shares

$1.95 Billion
25.41% of portfolio
Capital International Investors Los Angeles, CA

6.43M
Shares

$1.19 Billion
0.29% of portfolio
Hhlr Advisors, Ltd. Grand Cayman, E9

5.18M
Shares

$956 Million
26.65% of portfolio
Primecap Management CO Pasadena, CA

4.97M
Shares

$919 Million
0.84% of portfolio
Baillie Gifford & CO

3.71M
Shares

$684 Million
0.64% of portfolio

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.2B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Central Trust CO, based on Form 13F filings with the SEC.

News

Stay updated on Central Trust CO with notifications on news.

Account